Zhengye Biotechnology Holding Limited (ZYBT) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
ZYBT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZYBT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZYBT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $167M | 23.3 | -Best | -40% | |
| $589M | 9.2Lowest | -Best | +225%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See ZYBT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZYBT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZYBT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZYBT — Frequently Asked Questions
Quick answers to the most common questions about buying ZYBT stock.
Is ZYBT stock overvalued or undervalued?
ZYBT current P/E: N/A. 5-year average P/E: N/A. Percentile: N/A.
How does ZYBT's valuation compare to peers?
Zhengye Biotechnology Holding Limited P/E of N/A compares to sector median of 22.3x. Sector comparison provides relative valuation context.
What is ZYBT's PEG ratio?
ZYBT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.